UNSPSC 51322601: Citiolone

This classification denotes a hepatoprotective agent and expectorant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70JKL15MUH. European Medicines Agency schedules Citiolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06633MIG. Citiolone generally arises in the molecular formula C6H9NO2S.

UNSPSC 51322601 Citiolone, a Commodity code, covers emergency medical and pharmaceutical supplies that state and local governments procure for fire rescue operations, emergency medical services, and health agency programs. State and local purchasing bodies solicit under this code for specific medications in standardized units—epinephrine, labetalol, adenosine, diltiazem, and other advanced life support agents—with strict expiration, storage, and delivery requirements. Issuing bodies include municipal fire departments and rescue services, state health and human services agencies, and cooperative purchasing alliances spanning multiple jurisdictions. The City of Tampa's Fire Rescue and the Texas Health and Human Services Commission represent the institutional buyers active in this space, with purchasing driven by emergency response readiness and pharmacy benefit program administration rather than routine clinical supply chains.

Recent activity concentrates in Florida and Texas, with multistate cooperative purchasing expanding the geographic footprint across Oregon and participating MMCAP member jurisdictions. The City of Tampa issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications with a due date of April 8, 2026, targeting four specific medication line items for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year base term plus renewal options; the solicitation includes a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness set for July 1, 2026, and pricing weighted at 75 percent of evaluation. The Texas HHS Commission posted a Request for Information (RHI No. HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling early-stage procurement design for a broader state pharmacy initiative.